Magnesium sulfate administration
Phase 3Small molecule
Magnesium sulfate administration is one of 6 small molecule programs targeting Severe Pre-Eclampsia. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Severe Pre-Eclampsia
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Normodyne
AAlvogen Korea
Approved
Lanoxin
AAdvanz Pharma
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Magnesium sulfate administration
UUniversity of California, San Francisco
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Severe Pre-Eclampsia1 trial
Serum Magnesium Level Administration in Severe Pre-eclampsia Obese Pregnancy
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·N/A·NCT03661775·60 enrolled
Atrial Fibrillation1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details